Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol
Khondrion announces that the European Medicines Agency (EMA) has accepted its Paediatric Investigation Plan (PIP) for the development of its wholly-owned lead asset, sonlicromanol, for children.
Bekijk nieuws